A monoclonal IgG 1 antibody that selectively inhibits InterleukinA and interleukin 17F.



It is an investigational humanized monoclonal immunoglobulin (Ig)G1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F, both of which are considered to be two key cytokines driving inflammatory processes.



Bimekizumab-treated patients demonstrate superior skin clearance at Week 16 versus patients treated with adalimumab (Humira, AbbVie) and placebo as measured by the Psoriasis Severity Index.



In two studies, bimekizumab-treated patients demonstrated total skin clearance at Week 16 (PASI 100), verifying superiority over ustekinumab (Stelara).



Leave a Reply

Your email address will not be published. Required fields are marked *